

Radioimmunotherapy

[View the current Radioimmunotherapy InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Radioimmunotherapy.html)

(<http://www.bioportfolio.com/indepth/Radioimmunotherapy.html>)

Radio immunotherapy utilizes an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells.

Recent Publications on Radioimmunotherapy:



- [Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.](#)
*PURPOSE OF REVIEW: The goal of this review is to update ophthalmologists...*4th October, 2008
Section of Ophthalmology, The University of Texas M.D. Anderson Cancer- *Curr Opin Ophthalmol.* 2008 Sep;19(5):414-21. ([DOI Direct Link](#))
- [Methylated bismuth, but not bismuth citrate or bismuth glutathione, induces cyto- and genotoxic effects in human cells in vitro.](#)
*Bismuth compounds are widely used in industrial processes and products. In...*2nd October, 2008
Institute of Hygiene and Occupational Health, University Hospital,- *Chem Res Toxicol.* 2008 Jun;21(6):1219-28. ([DOI Direct Link](#))
- [Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.](#)
*PURPOSE: Studies herein explore paclitaxel enhancement of the therapeutic...*1st October, 2008
Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch,- *Clin Cancer Res.* 2008 Aug 15;14(16):5108-15. ([DOI Direct Link](#))
- [\[Clinical indications of radioimmunotherapy in lymphoma\]](#)
*In their later stages low grade lymphoma are incurable. These lymphomas...*26th September, 2008
Service de medecine nucleaire, CHU de Liege, Sart Tilman, 4000 Liege,- *Rev Med Suisse.* 2008 Aug 27;4(168):1818-22.
- [Radioisotopic Localization of \(90\)Yttrium-Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin's Lymphoma.](#)
*PURPOSE: (90)Yttrium-ibritumomab-tiuxetan (Zevalin) is an effective...*6th September, 2008
Division of Hematology/Oncology, University of Pittsburgh Medical Center,- *Mol Imaging Biol.* 2008 Sep 5. ([DOI Direct Link](#))
- [Tumor targeting by a multivalent single-chain Fv \(scFv\) anti-Lewis Y antibody construct.](#)
*The use of single-chain variable fragment (scFv) constructs has been...*6th September, 2008
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin- *Cancer Biother Radiopharm.*

- 2008 Aug;23(4):411-23. ([DOI Direct Link](#))
- [Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.](#)
*OBJECTIVE: The 4.2-day half-life of (124)I favors its use for positron...*6th September, 2008
Department of Radioimmunotherapy, City of Hope, Duarte, CA 91010-3000,- Cancer Biother Radiopharm. 2008 Aug;23(4):399-409. ([DOI Direct Link](#))
 - [Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?](#)
*The cytotoxic potency of a molecule can be augmented by conjugating a...*6th September, 2008
Department of Internal Medicine, University of California, Davis,- Cancer Biother Radiopharm. 2008 Aug;23(4):383-97. ([DOI Direct Link](#))
 - [Aiming at a curative strategy for follicular lymphoma.](#)
*Follicular lymphoma is often managed as an incurable disease. However, a...*30th August, 2008
Immunotherapy Program, Cell Therapy Area, University of Navarra Hospital,- CA Cancer J Clin. 2008 Sep-Oct;58(5):305-17. Epub 2008 Aug 28. ([DOI Direct Link](#))
 - [Thyroid cancer: The impact of emerging technologies on clinical practice guidelines.](#)
*Clinical practice guidelines are available for the evaluation and...*30th August, 2008
Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School- Biomed Pharmacother. 2008 Aug 5. ([DOI Direct Link](#))
 - [The Effects of Adjuvant Experimental Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy on Intestinal and Abdominal Healing after Cytoreductive Surgery for Peritoneal Carcinomatosis in the Rat.](#)
*BACKGROUND: Cytoreductive surgery (CS) followed by hyperthermic...*21st August, 2008
Department of Surgery, Radboud University Nijmegen Medical Centre,- Ann Surg Oncol. 2008 Aug 19. ([DOI Direct Link](#))
 - [Management of relapsed diffuse large B-cell lymphoma.](#)
*Despite more effective front-line regimens, a substantial portion of...*19th August, 2008
Section of Hematology/Oncology, Department of Medicine, The University of- Curr Oncol Rep. 2008 Sep;10(5):393-403.
 - [Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.](#)
*Our goals in this study were to determine whether (111)In-trastuzumab...*16th August, 2008
Leslie Dan Faculty of Pharmacy, Department of Pharmaceutical Sciences,- J Nucl Med. 2008 Sep;49(9):1498-505. Epub 2008 Aug 14. ([DOI Direct Link](#))
 - [Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.](#)
*Multidrug resistance (MDR) is a major challenge to the successful...*16th August, 2008
Department of Pharmaceutical Sciences, University of Toronto, Toronto,- J Nucl Med. 2008 Sep;49(9):1546-54. Epub 2008 Aug 14. ([DOI Direct Link](#))
 - [Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy.](#)
*Radioimmunotherapy (RIT) is a method for selectively delivering...*15th August, 2008
Division of Hematology and Oncology, Internal Medicine, University of- Bioorg Med Chem Lett. 2008 Sep 1;18(17):4802-5. Epub 2008 Jul 30. ([DOI Direct Link](#))

BioNews Results for Radioimmunotherapy

- [Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidati](#)
Pharma Live: Oct 3 2008 9:23AM Matching: radioimmunotherapy
- [Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line](#)

[Consolidati](#)

KRON4: Oct 2 2008 8:34AM Matching: radioimmunotherapy

- [Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidati](#)

Montana's News Station: Oct 2 2008 7:29AM Matching: radioimmunotherapy

- [Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidati](#)

KSLA: Oct 2 2008 7:28AM Matching: radioimmunotherapy

- [Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidati](#)

KLFY: Oct 2 2008 6:49AM Matching: radioimmunotherapy

Radioimmunotherapy Clinical Trials:



- [BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma](#)

Lymphoma Intervention: Radiation: 131Iodine-Anti-B1 Radioimmunotherapy

Radioimmunotherapy Patents:



- 7344829- [Methods for detecting the efficacy of anticancer treatments](#)
- 7374778- [Enhanced transport using membrane disruptive agents](#)
- 7374936- [Method and means for site directed therapy](#)
- 7378056- [Circuits for in vivo detection of biomolecule concentrations using fluorescent tags](#)
- 7378077- [High dose radionuclide complexes for bone marrow suppression](#)
- 7378091- [Antibodies against carbonic anhydrase IX \(CA IX\) tumor antigen](#)
- 7378249- [Treatment of cancer using TLR3 agonists](#)
- 7378253- [Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells](#)
- 7381560- [Expression and use of anti-CD20 antibodies](#)
- 7385035- [Cytotoxic protein and utilization thereof](#)
- 7387772- [Chimeric, human and humanized anti-CSAP monoclonal antibodies](#)
- 7371723- [Therapeutic agents comprising pro-apoptotic proteins](#)
- 7371371- [Interleukin-2 mutants with reduced toxicity](#)
- 7368293- [Liver enriched transcription factor](#)
- 7348001- [Tie1-binding ligands](#)
- 7348010- [Vaccine against cancer diseases that are associated with the her-2/neu oncogene](#)
- 7354762- [Method for producing CE7-specific redirected immune cells](#)
- 7354897- [Method and composition for inhibiting or slowing blood coagulation](#)

- [7358353- Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers](#)
- [7361338- Methods to inhibit growth of prostate cancer cells](#)
- [7361347- Cytotoxic CD44 antibody immunoconjugates](#)
- [7361475- Compositions and methods relating to colon specific genes and proteins](#)
- [7365054- Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies](#)
- [7368100- Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same](#)
- [7390635- Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides](#)
- [7393527- Method for limiting the growth of cancer cells using an attenuated measles virus](#)
- [7420040- Cytotoxicity mediation of cells evidencing surface expression of TROP-2](#)
- [7420041- Cytotoxicity mediation of cells evidencing surface expression of TROP-2](#)
- [7422738- Combined cancer treatment methods using antibodies to aminophospholipids](#)
- [7422739- Anti-CD20 antibodies](#)
- [7423114- GD2 ligands](#)
- [7425317- Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy](#)
- [7425618- Stabilized anti-respiratory syncytial virus \(RSV\) antibody formulations](#)
- [7427399- Antibodies and related molecules that bind to 161P2F10B proteins](#)
- [7427665- Chronic lymphocytic leukemia cell line](#)
- [7429381- Production and use of novel peptide-based agents for use with bi-specific antibodies](#)
- [7417127- Antibodies specific for CD44v6](#)
- [7414121- Chimeric, human and humanized anti-CSAp monoclonal antibodies](#)
- [7410642- Assays and therapies for latent viral infection](#)
- [7396917- Rationally designed antibodies](#)
- [7399461- Prostate-specific membrane antigen and uses thereof](#)
- [7399835- Cancerous disease modifying antibodies](#)
- [7399849- Murine monoclonal anti-idiotypic antibody 11D10 and methods of use thereof](#)
- [7402385- Radiolabeled antibodies for treatment of tumors](#)
- [7402392- In vivo panning for ligands to radiation-induced molecules](#)
- [7405290- Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer](#)
- [7405320- Therapeutic and diagnostic conjugates for use with multispecific antibodies](#)
- [7408041- Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof](#)
- [7408046- Treatment of bone-associated cancers](#)
- [7429382- Antibodies that bind cell-associated CA 125/O772P and methods of use thereof](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

